Timothy Alexander

ICYMI: Medicus Advances SkinJect Into Registrational Study for Rare Disorder PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) has submitted a registrational study protocol to the U.S. Food and Drug Administration for its S […]

Madrigal Investors Focus on Rezdiffra Growth at Goldman Event CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) is set to present at the Goldman Sachs Global Healthcare Conference this week as i […]

Palvella Advances Rare Disease Drug Toward FDA Filing WAYNE, PA — Palvella Therapeutics Inc. (Nasdaq: PVLA) said it remains on track to submit a New Drug Application in the second half of 2026 for its l […]

Cabaletta Expands Autoimmune Strategy on Mid-Stage Data PHILADELPHIA, PA — Cabaletta Bio (Nasdaq: CABA) reported new clinical data suggesting its lead CAR-T cell therapy candidate could support regulatory f […]

Mineralys Restructures Drug Economics With $500 Million Financing RADNOR, PA — Mineralys Therapeutics (NASDAQ: MLYS) has agreed to eliminate future royalty obligations tied to its lead drug candidate lorundrostat w […]

Neuronetics Names Sales Chief, Grants Equity Incentive MALVERN, PA — Neuronetics Inc. (NASDAQ: STIM) has appointed healthcare sales executive Robert Greene as senior vice president of sales and awarded h […]

Orchestra BioMed Grants Equity Awards to New Employees NEW HOPE, PA — Orchestra BioMed Holdings Inc. (Nasdaq: OBIO) has granted stock options covering 85,500 shares to five newly hired employees, using an i […]

Callan Expands Advisory Services With Philanthropy Hire PHILADELPHIA, PA — Callan Family Office has hired philanthropic strategist George Burnette as director of philanthropic consulting and wealth, e […]

Obesity Survey Finds Gap Between Treatment Support and Use RADNOR, PA — New research comparing the views of primary care physicians and patients with obesity found broad acceptance of anti-obesity medications b […]

Angeion Names New CEO as Growth Strategy Enters Next Phase PHILADELPHIA, PA — Angeion Group has appointed veteran legal information executive Bill Carter as chief executive officer, a leadership change that s […]

Palvella Set for Goldman Conference Amid Rare Disease Push WAYNE, PA — Palvella Therapeutics (Nasdaq: PVLA) will present its development strategy to investors this week as the clinical-stage biotechnology c […]

SEED Advances Cancer Drug Into Human Trials, Targets Hard-to-Treat Tumors KING OF PRUSSIA, PA — SEED Therapeutics has advanced its lead cancer drug candidate, ST-01156, into a first-in-human clinical trial, a step that will t […]

BLAST Robotics Explores Partnership Opportunities With Penn State Great Valley MALVERN, PA — BLAST Robotics, a youth robotics program operated by Keystone STEM Alliance Inc., is exploring potential partnerships with Penn State G […]

London Britain Township: Inside Chester County's Most Carefully Preserved Rural Landscape On a cool morning in southern Chester County, mist hangs low over the meadows of White Clay Creek. The only sounds are the rush of water over stone, […]

Quavo Report Highlights Dispute Resolution Performance Gaps WILMINGTON, DE — Quavo Inc. recently released a new benchmarking study of fraud and dispute management programs, identifying key performance d […]

HHM Hotels Elevates Investment, Operations Chiefs to Managing Partners PHILADELPHIA, PA — HHM Hotels has promoted Chief Investment Officer Shawn Tuli and Chief Operating Officer Dani Elhachem to managing partners, a l […]

ICYMI: Enviri Completes Breakup, Launches New Public Company After Veolia Deal PHILADELPHIA, PA — Enviri II Corporation (NYSE: NVRI WI) recently completed its spin-off as a standalone publicly traded company and finalized the s […]

Aprea Reports Early Tumor Responses in Phase 1 APR-1051 Study DOYLESTOWN, PA — Aprea Therapeutics reported early signs of anti-tumor activity from its ongoing Phase 1 trial of experimental cancer therapy A […]

ICYMI: Lungpacer Hires Veteran Healthcare Executive as CFO Amid Commercial Push EXTON, PA — Lungpacer Medical has appointed healthcare finance executive Steven Pfanstiel as chief financial officer as the company moves to expand c […]

Incyte Study Shows Lymphoma Regimen Extends Progression-Free Survival WILMINGTON, DE — Incyte reported Phase 3 trial results showing that adding tafasitamab and lenalidomide to the standard R-CHOP regimen reduced the r […]